A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

An Enzymatic Method to Rescue Mesenchymal Stem Cells from Clotted Bone Marrow Samples

9.1K views

⸱

DOI:

10.3791/52694

⸱

April 12th, 2015

 ,  ,  ,  ,  ,  , 

* These authors contributed equally

In This Article

Summary

Mesenchymal stem cells are usually obtained from bone marrow and require expansion culture. When samples clot before processing, a protocol using the (enzymatic) thrombolytic drug urokinase can be applied to degrade the clot. Thus, cells are released and available for expansion culture. This protocol provides a rapid and inexpensive alternative to resampling.

Abstract

Mesenchymal stem cells (MSCs) - usually obtained from bone marrow - often require expansion culture. Our protocol uses clinical grade urokinase to degrade clots in the bone marrow and release MSCs for further use. This protocol provides a rapid and inexpensive alternative to bone marrow resampling. Bone marrow is a major source of MSCs, which are interesting for tissue engineering and autologous stem cell therapies. Upon withdrawal bone marrow may clot, as it comprises all of the hematopoietic system. The resulting clots contain also MSCs that are lost for expansion culture or direct stem cell therapy. We experienced that 74% of canine bone marrow samples contained clots and yielded less than half of the stem cell number expected from unclotted samples. Thus, we developed a protocol for enzymatic digestion of those clots to avoid labor-intense and costly bone marrow resampling. Urokinase - a clinically approved and readily available thrombolytic drug – clears away the bone marrow clots almost completely. As a consequence, treated bone marrow aspirates yield similar numbers of MSCs as unclotted samples. Also, after urokinase treatment the cells kept their metabolic activity and the ability to differentiate into chondrogenic, osteogenic and adipogenic lineages. Our protocol salvages clotted blood and bone marrow samples without affecting the quality of the cells. This obsoletes resampling, considerably reduces sampling costs and enables the use of clotted samples for research or therapy.

Introduction

Mesenchymal stem cells (MSCs) play a major role in regenerative medicine and tissue engineering. They can migrate, differentiate into various cell types 1 and engraft, which renders them the ideal candidates for autologous therapies 2,3. Lately, clinical trials using MSCs for bone and cartilage repair, graft versus host disease or heart disease were launched 4. These MSCs can be harvested from the umbilical cord or adipose tissue but most promising results were obtained from bone marrow derived stem cells 5.

The iliac crest allows to collect a considerable amount of bone marrow and therefore serve....

Access restricted. Please log in or start a trial to view this content.

Protocol

NOTE: Human bone marrow aspirates from the iliac crest were collected from consenting donors with the approval of the ethics committee of the canton of Lucerne. Canine bone marrow aspirates from the iliac crest were collected with dog owner’s consent.Human (approx. 20 ml) and canine (approx. 10 ml) bone marrow aspirates were anti-coagulated by addition of 15 ml of 3.8% sodium citrate immediately after withdrawal in the operation theatre. The samples were transferred to the laboratory environment for processing the same day as withdrawn.

1. Preparation of Urokinase (Prior to 1st Use)

  1. Reconstitute urokinase using ....

Access restricted. Please log in or start a trial to view this content.

Results

The facts that 74% of canine bone marrow samples (n=54) contained clots when they arrived in our laboratory (Figure 1A) along with decreased MSC yields from these samples, made us believe that a considerable number of MSCs was trapped within the clots. Indeed, a simple DAPI-stain of sectioned clot material confirms the presence of nucleated cells in high density (Figure 1B). This ultimately leads to low numbers of MSCs available for expansion culture, which triggered us to develop the pr.......

Access restricted. Please log in or start a trial to view this content.

Discussion

Routinely we sample bone marrow while the patient is undergoing surgery (in our case mainly spine surgery), with the advantage that only little additional work has to be carried out by the personnel in the operation theatre. Even though the samples are mixed with sodium citrate immediately after withdrawal, many samples were partially clotted when they arrived in the laboratory for processing. At this stage, resampling to replace clotted specimens would be a separate additional intervention necessitating again local or g.......

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors have nothing to disclose.

Acknowledgements

This work was supported by the Swiss National Foundation Grant CR3I3_140717/1 and the Swiss Paraplegic Foundation.

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
Basal Medium Components
PenStrep 100XGibco15140122
Human FGF-basicPeprotech100-18B
MEM Alpha w/ Nucleoside, w/ stable GlutamineAmimed1-23S50-I
FBS Heat InactivatedAmimed2-01F36-I
Amphotericin BApplichemA1907
Adipogenic Medium Components
DMEM-HAM F12 + GlutaMAXAmimed1-26F09-I
Insulin SigmaI5500
Rabbit serum Gibco16120099
DexamethasoneApplichemD4902
3-Isobutyl-1-methylxanthineSigmaI5879
Biotin SigmaB4639
Rosiglitazone SigmaR2408
Pantothenate SigmaP5155
Oil Red-O SigmaO0625
Osteogenic Medium Components
L-ascorbic acid 2-phosphateSigmaA8960
ß-glycerophosphateSigmaG9422
Silver nitrate (AgNO3)SigmaS6506
Chondrogenic Medium Components
Biopad - sponge shaped medical device Euroresearch
L-proline SigmaP5607
Insulin-Transferrin-Selenium XGibco51500056
Human transforming growth factor-β1 Peprotech100-21
Alcian Blue 8GXSigmaA3157
Nuclear fast redSigmaN8002
Generic
Tri-Sodium citrate dihydrateApplichemA3901
PBSApplichem964.9100
UrokinaseMedac1976826
0.5% Trypsin-EDTAGibco15400054
Giemsa stainApplichemA0885
FormaldehydeApplichemA0877
Sulfuric acid (H2SO4)ApplichemA0655
Dimethyl sulfoxide (DMSO)ApplichemA1584
Magnesium chloride (MgCl2)ApplichemA3618
Guanidine hydrochlorideApplichemA1499
Consumables
50 ml reaction tubeAxygenSCT-50ML-25-S
10 ml syringeBraun4606108V
Sterican needle (22G)Braun4657624
1.7 ml MicrotubesBrunschwigMCT-175-C
100 μm cell strainerFalcon6.05935
sterile forcepsBastos Viegas, SA489-001
sterile scalpelBraun5518059
Primaria cell cuture dishFalcon353803
C-Chip Neubauer ImprovedBioswisstech505050
cell culture flask - Flask T300TPP90301
Equipment
Microbiological biosafety cabinet class IISkan82011500
water bathMemmert1305.0377
Stripettes Serological Pipette 5mlCorning4487-200ea
microscopeOlympusCKX41
humidified incubator Heracells 240Thermo scientific51026331
Heraeus Multifuge 1S-RThermo scientific75004331

References

  1. Jiang, Y., et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 418 (6893), 41-49 (2002).
  2. Uccelli, A., Moretta, L., Pistoia, V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 8 (9), 726-736 (2008).
  3. Bartholomew, A., e....

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Explore More Articles

Urokinase DigestionClot DegradationCell Strainer FiltrationCFU AssayAdipogenic DifferentiationOsteogenic DifferentiationChondrogenic DifferentiationExpansion Culture